Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.

@article{Tobinai1998FeasibilityAP,
  title={Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.},
  author={Kensei Tobinai and Yutaka Kobayashi and Masaru Narabayashi and Michinori Ogura and Yoshitoyo Kagami and Yasuo Morishima and Tomoko Ohtsu and Tadahiko Igarashi and Yuki Sasaki and Tomohiro Kinoshita and Takanao Murate},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1998},
  volume={9 5},
  pages={527-34}
}
BACKGROUND In clinical trials in the USA, IDEC-C2B8 (a mouse-human chimeric anti-CD20 monoclonal antibody) has demonstrated high response rates with only mild toxic effects in relapsed B-cell lymphoma at a dose of four weekly 375 mg/m2 infusions. The aim of the present trial was to determine whether or not this dose is practically applicable to Japanese patients with relapsed B-cell lymphoma with respect to safety, pharmacokinetics and efficacy. PATIENTS AND METHODS Patients with relapsed… CONTINUE READING